Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial
Background. Dual antiplatelet therapy with a P2Y12 inhibitor (e.g., clopidogrel and ticagrelor) and aspirin is recommended for at least one year after percutaneous coronary intervention (PCI) to prevent further myocardial infarction and stent thrombosis as the major adverse effects of PCI. Methods....
Saved in:
Main Authors: | Mohammadjavad Mehdizadeh Parizi, Reza Golchin Vafa, Amin Ahmadi, Reza Heydarzade, Mehrdad Sadeghi, Amin Khademolhossseini, Farhang Amiri, Soroush Khoshnood Mansorkhani, Ali Tavan, Nazanin Hosseini, Mohammad Montaseri, Seyed Ali Hosseini, Javad Kojuri |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Journal of Interventional Cardiology |
Online Access: | http://dx.doi.org/10.1155/2023/5544440 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
by: Peixun He, et al.
Published: (2021-01-01) -
Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
by: Bartosz Olechowski, et al.
Published: (2016-01-01) -
The Effect of Clopidogrel and Ticagrelor on Human Adipose Mesenchymal Stem Cell Osteogenic Differentiation Potential: In Vitro Comparative Study
by: Sally S. Mohamed, et al.
Published: (2024-01-01) -
Migratory Polyarthritis Associated With Clopidogrel: A Case Report
by: Hamid Khederlou, et al.
Published: (2024-12-01) -
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
by: Arwa M. Amin, et al.
Published: (2017-01-01)